Evidence map›Paper›PMID 28355876›Full record

ArticleJournal of the American Chemical Society2017

Diverse Redoxome Reactivity Profiles of Carbon Nucleophiles.

Vinayak Gupta, Jing Yang, Daniel C Liebler, Kate S Carroll

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Assays of Thiol Isomerase Activity.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  7. Article
  8. Profiling the landscape of cysteine posttranslational modifications in brain aging and neurodegeneration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Targeting Cysteine Oxidation in Thrombotic Disorders.Antioxidants (Basel, Switzerland) · 2024
    Review
  13. Article
  14. Flipping the polarity switch.Nature chemical biology · 2023
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vinayak GuptaDepartment of Chemistry, The Scripps Research Institute , Jupiter, Florida 33458, United States.ORCID 0000-0003-1567-1037
Jing YangState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences , Beijing 102206, China.ORCID 0000-0001-8486-273X
Daniel C LieblerDepartment of Biochemistry, Vanderbilt University School of Medicine , Nashville, Tennessee 37232, United States.ORCID 0000-0002-7873-3031
Kate S CarrollDepartment of Chemistry, The Scripps Research Institute , Jupiter, Florida 33458, United States.ORCID 0000-0002-7624-9617

Funding

Probing the role of cysteine sulfenylation in cell signalingR01GM102187 · NIGMS · UNIVERSITY OF FLORIDA · PI Kate Suzanne Carroll · 2012 to 2026
$4.6M
Nucleophilic Inhibitors for Targeting Redox-Sensitive KinasesR01CA174864 · NCI · SCRIPPS FLORIDA · PI CARROLL, KATE SUZANNE · 2014 to 2017
$1.6M
NCI NIH HHS R01 CA174864NIGMS NIH HHS R01 GM102187
6 · The paper itself

Abstract

Targeted covalent inhibitors have emerged as a powerful approach in the drug discovery pipeline. Key to this process is the identification of signaling pathways (or receptors) specific to (or overexpressed in) disease cells. In this context, fragment-based ligand discovery (FBLD) has significantly expanded our view of the ligandable proteome and affords tool compounds for biological inquiry. To date, such covalent ligand discovery has almost exclusively employed cysteine-reactive small-molecule fragments. However, functional cysteine residues in proteins are often redox-sensitive and can undergo oxidation in cells. Such reactions are particularly relevant in diseases, like cancer, which are linked to excessive production of reactive oxygen species. Once oxidized, the sulfur atom of cysteine is much less reactive toward electrophilic groups used in the traditional FBLD paradigm. To address this limitation, we recently developed a novel library of diverse carbon-based nucleophile fragments that react selectively with cysteine sulfenic acid formed in proteins via oxidation or hydrolysis reactions. Here, we report analysis of sulfenic acid-reactive C-nucleophile fragments screened against a colon cancer cell proteome. Covalent ligands were identified for >1280 S-sulfenylated cysteines present in "druggable" proteins and orphan targets, revealing disparate reactivity profiles and target preferences. Among the unique ligand-protein interactions identified was that of a pyrrolidinedione nucleophile that reacted preferentially with protein tyrosine phosphatases. Fragment-based covalent ligand discovery with C-nucleophiles affords an expansive snapshot of the ligandable "redoxome" with significant implications for covalent inhibitor pharmacology and also affords new chemical tools to investigate redox-regulation of protein function.

Indexed as

CarbonColonic NeoplasmsCysteineDrug DiscoveryHumansLigandsMolecular StructureOxidation-ReductionProteomeSulfenic AcidsCarbonCysteinecysteinesulfenic acidLigandsProteomeSulfenic Acids

Identifiers

PMID28355876
PMCPMC5898444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.